Tivantinib: Phase III started

Kyowa Hakko began the double-blind, Asian Phase III ATTENTION trial to compare twice-daily oral tivantinib plus once-daily oral erlotinib vs. placebo plus erlotinib in about 460 patients with locally advanced or metastatic, non-squamous NSCLC with wild-type EGFR who have received 1-2 prior systemic cancer therapies. ArQule is co-developing tivantinib with Daiichi Sankyo on a worldwide basis outside of certain Asian countries, where ArQule licensed rights to Kyowa in 2007 (see BioCentury, Nov. 17, 2008). ...